Evidence map›Paper›PMID 34178875›Full record

ArticleJournal of diabetes and metabolic disorders2021

Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment.

Zahra Hoseini-Tavassol, Shirin Hasani-Ranjbar

Open access · greenAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Role of glycolysis in diabetic atherosclerosis.World journal of diabetes · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zahra Hoseini-TavassolObesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Shirin Hasani-RanjbarObesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7448-8510
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the prevalence of cardiovascular diseases (CVDs), as one of the most important non-communicable diseases (NCDs), the recognition of diagnostic biomarkers and potential treatment methods is very crucial. Today gut microbiota composition and its derived metabolites modification are known as one of the recent therapeutic strategies. Studies show that Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite that may be involved in the development of cardiovascular diseases, including ischemic disease and atherosclerosis, atrial fibrillation and arrhythmia, and heart failure. Due to existing some disagreements in this manner, future studies are needed to obtain a definitive sight of the association between this metabolite and CVDs. TMAO may be beneficial as a prognostic marker, which represents the degree of gut microbiota dysbiosis and subsequently CVD events and also different therapies methods based on TMAO and its metabolic pathways can be the target of clinical trial on cardiovascular disease and/or its prevention.

Indexed as

BiomarkersCardiovascular diseaseGut MicrobiotaTherapeuticsTrimethylamine N-oxide (TMAO)

Identifiers

PMID34178875
PMCPMC8212337
OpenAlexW3163378034

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.